Trials / Terminated
TerminatedNCT04047771
A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis
A Phase I Study Evaluating the Safety, Tolerability and Pharmacokinetics of SCB-313, Recombinant Human Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Trimer Fusion Protein, for the Treatment of Subjects With Peritoneal Carcinomatosis
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Sichuan Clover Biopharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of SCB-313 in patients with peritoneal carcinomatosisa, to determine the maximum tolerated dose (MTD) and/or extended study recommended dose (RDE) for SCB-313 intraperitoneal injection, providing a basis for dosing regimen and dose choosing in clinical trial subsequently.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SCB-313 | Intraperitoneal injection, 3 doses on D1,D4,D7，21 days for 1 cycle |
Timeline
- Start date
- 2019-09-10
- Primary completion
- 2022-05-05
- Completion
- 2022-05-05
- First posted
- 2019-08-07
- Last updated
- 2023-04-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04047771. Inclusion in this directory is not an endorsement.